OpenLB
Open Library of Bioscience
Advanced Search
Journal of applied oral science : revista FOB
2022;30 e20220020.

Autologous platelet concentrates for facial rejuvenation.

Marília Afonso Rabelo Buzalaf, Flávia Mauad Levy
Author Information
  1. Marília Afonso Rabelo Buzalaf: Universidade de São Paulo, Faculdade de Odontologia de Bauru, Departamento de Ciências Biológicas, Bauru, SP, Brasil. ORCID
  2. Flávia Mauad Levy: Universidade de São Paulo, Faculdade de Odontologia de Bauru, Departamento de Ciências Biológicas, Bauru, SP, Brasil. ORCID
PMID: 36074433 DOI: 10.1590/1678-7757-2022-0020

Abstract

BACKGROUND: Autologous platelet concentrates (APCs) are promising therapeutic agents in facial rejuvenation since they are a great source of cytokines, growth factors and other biologically active substances. Obtained from the patient's blood, they have the advantages of reducing immunological reactions, making the procedure safer, well tolerated, with minimal adverse effects and lower cost. Currently, they are used for facial rejuvenation both in combination with microneedling and in mesotherapy techniques, as well as to treat facial acne scars, melasma and wounds after laser ablative treatments. This review summarizes current knowledge on the use of APCs, ranging from basic concepts related to their composition and mechanisms of action to up-to-date information on their clinical efficacy.
METHODOLOGY: MEDLINE (PubMed) was searched from inception through 2021 for English language publications on APCs for facial rejuvenation.
RESULTS: A total of 100 files were found. Based on the available literature, APCs for skin rejuvenation are safe and well tolerated. The most studied product is the first-generation material, platelet-rich plasma (PRP).
CONCLUSIONS: The results are in general favorable, but the quality of the studies is low. The second and third generation products, platelet-rich fibrin (PRF) and injectable platelet-rich fibrin (i-PRF), respectively, are easier to be obtained and, at least in vitro , seem to induce greater collagen production than PRP, especially under lower relative centrifugation forces, but to date only a few clinical trials evaluating these products exist. More high-quality trials with appropriate follow-up are necessary to provide adequate evidence that may help to improve the treatment regimens with APCs. Many aspects should be considered when designing clinical trials to evaluate APCs, such as the patients' characteristics that best predict a favorable response, the optimal number of sessions and the interval between them, the characteristics of the studies and the development of better instruments to evaluate skin aging.

References

  1. J Cosmet Dermatol. 2019 Aug;18(4):1105-1112 [PMID: 30280483]
  2. Ann Surg. 1986 Sep;204(3):322-30 [PMID: 3753059]
  3. Arch Dermatol Res. 2021 Dec;313(10):863-871 [PMID: 33550448]
  4. Arthroscopy. 2014 May;30(5):629-38 [PMID: 24725317]
  5. Eur J Trauma Emerg Surg. 2019 Jun;45(3):467-479 [PMID: 28324162]
  6. J Craniofac Surg. 2017 Nov;28(8):e793 [PMID: 27438442]
  7. Dermatol Surg. 2017 Jun;43(6):826-835 [PMID: 28375975]
  8. Aesthet Surg J. 2021 Jun 14;41(7):NP854-NP865 [PMID: 33534905]
  9. Aesthetic Plast Surg. 2015 Aug;39(4):495-505 [PMID: 26044392]
  10. J Cosmet Dermatol. 2019 Feb;18(1):77-83 [PMID: 29855132]
  11. Dermatol Surg. 2011 Apr;37(4):463-8 [PMID: 21481064]
  12. J Cosmet Laser Ther. 2014 Oct;16(5):206-8 [PMID: 25065381]
  13. Int J Mol Med. 2012 Jan;29(1):32-6 [PMID: 21964487]
  14. Arch Dermatol Res. 2022 Sep;314(7):661-671 [PMID: 34231136]
  15. J Cosmet Dermatol. 2014 Mar;13(1):72-8 [PMID: 24641609]
  16. Eur J Trauma Emerg Surg. 2018 Feb;44(1):87-95 [PMID: 28283682]
  17. Implant Dent. 2001;10(4):225-8 [PMID: 11813662]
  18. J Drugs Dermatol. 2010 May;9(5):466-72 [PMID: 20480789]
  19. Mech Ageing Dev. 2002 Apr;123(7):801-10 [PMID: 11869737]
  20. J Cosmet Dermatol. 2022 May;21(5):2038-2045 [PMID: 34214220]
  21. J Cosmet Dermatol. 2021 Sep;20(9):2712-2714 [PMID: 34214233]
  22. Arthroscopy. 2012 Jul;28(7):998-1009 [PMID: 22738751]
  23. J Orthop Res. 2008 Mar;26(3):404-10 [PMID: 17960651]
  24. Rheumatology (Oxford). 2007 Dec;46(12):1769-72 [PMID: 17942474]
  25. Dermatol Surg. 2014 Feb;40(2):152-61 [PMID: 24354616]
  26. Acta Biomed. 2021 May 12;92(2):e2021187 [PMID: 33988167]
  27. Int J Dermatol. 2018 Nov;57(11):1324-1334 [PMID: 30105816]
  28. Oncotarget. 2017 Jul 31;8(40):68542-68556 [PMID: 28978136]
  29. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):638-46 [PMID: 9638695]
  30. J Cosmet Dermatol. 2019 Dec;18(6):2004-2010 [PMID: 30990574]
  31. J Cosmet Dermatol. 2021 Aug;20(8):2431-2436 [PMID: 34013618]
  32. Eur Spine J. 2004 Oct;13 Suppl 1:S102-6 [PMID: 15221571]
  33. Int J Oral Maxillofac Surg. 2005 Jun;34(4):420-4 [PMID: 16053853]
  34. Nature. 1954 Apr 17;173(4407):723-4 [PMID: 13165629]
  35. Tissue Eng Part C Methods. 2012 Mar;18(3):176-85 [PMID: 21951067]
  36. J Cosmet Dermatol. 2017 Mar;16(1):103-111 [PMID: 27474688]
  37. J Cosmet Dermatol. 2017 Mar;16(1):112-119 [PMID: 27595866]
  38. Aesthet Surg J. 2021 Jun 14;41(7):747-758 [PMID: 32816021]
  39. J Cosmet Dermatol. 2020 Aug;19(8):1975-1979 [PMID: 31833646]
  40. JAMA Dermatol. 2018 Dec 1;154(12):1447-1452 [PMID: 30419125]
  41. Clin Oral Investig. 2017 Jul;21(6):1913-1927 [PMID: 28551729]
  42. BMJ Open Sport Exerc Med. 2016 Feb 4;2(1):e000060 [PMID: 27900152]
  43. J Am Acad Dermatol. 2017 Sep;77(3):584-586 [PMID: 28807118]
  44. Arch Dermatol Res. 2020 Jul;312(5):301-315 [PMID: 31628542]
  45. J Clin Invest. 2005 Dec;115(12):3370-7 [PMID: 16322782]
  46. Aesthet Surg J. 2017 Mar 1;37(3):353-362 [PMID: 28207031]
  47. J Cosmet Dermatol. 2020 Dec;19(12):3213-3221 [PMID: 32852873]
  48. Aesthet Surg J. 2016 Mar;36(3):261-70 [PMID: 26879294]
  49. J Oral Maxillofac Surg. 2004 Apr;62(4):489-96 [PMID: 15085519]
  50. Dermatol Ther. 2020 Nov;33(6):e13906 [PMID: 32594637]
  51. Dermatol Surg. 2020 Mar;46(3):348-357 [PMID: 31714381]
  52. Curr Opin Hematol. 2009 Sep;16(5):329-33 [PMID: 19550320]
  53. J Cosmet Dermatol. 2020 Jan;19(1):185-189 [PMID: 31674154]
  54. Platelets. 2018 Jan;29(1):48-55 [PMID: 28351189]
  55. J Cosmet Dermatol. 2019 Aug;18(4):985-995 [PMID: 30350908]
  56. Plast Reconstr Surg. 2004 Nov;114(6):1502-8 [PMID: 15509939]
  57. J Mater Sci Mater Med. 2017 Oct 25;28(12):188 [PMID: 29071440]
  58. Plast Reconstr Surg. 2006 Nov;118(6):147e-159e [PMID: 17051095]
  59. J Cosmet Laser Ther. 2019;21(6):309-315 [PMID: 31064236]
  60. Ann Dermatol. 2011 Nov;23(4):424-31 [PMID: 22148008]
  61. Wound Repair Regen. 2002 Sep-Oct;10(5):336-40 [PMID: 12406171]
  62. Dermatol Surg. 2012 Jul;38(7 Pt 1):1040-6 [PMID: 22455565]
  63. Orthop J Sports Med. 2017 Jan 03;5(1):2325967116675272 [PMID: 28210651]
  64. Aesthetic Plast Surg. 2014 Oct;38(5):1057-63 [PMID: 24984784]
  65. Cell Physiol Biochem. 2018;47(1):316-329 [PMID: 29768259]
  66. Ann Dermatol. 2016 Dec;28(6):718-724 [PMID: 27904271]
  67. J Cosmet Dermatol. 2017 Jun;16(2):258-264 [PMID: 28382785]
  68. Knee Surg Sports Traumatol Arthrosc. 2011 Apr;19(4):516-27 [PMID: 21082164]
  69. Biomed Res Int. 2018 May 21;2018:6389157 [PMID: 29951539]
  70. J Eur Acad Dermatol Venereol. 2014 Jan;28(1):72-9 [PMID: 23279091]
  71. Platelets. 2012;23(3):217-23 [PMID: 21913811]
  72. Rejuvenation Res. 2017 Feb;20(1):25-31 [PMID: 27222038]
  73. J Cosmet Dermatol. 2010 Mar;9(1):66-71 [PMID: 20367676]
  74. Eur J Dermatol. 2014 Jan-Feb;24(1):100-1 [PMID: 24566300]
  75. Exp Ther Med. 2020 Apr;19(4):3024-3030 [PMID: 32256789]
  76. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97 [PMID: 25722595]
  77. Curr Pharm Biotechnol. 2012 Jun;13(7):1131-7 [PMID: 21740379]
  78. Aesthetic Plast Surg. 2018 Apr;42(2):511-519 [PMID: 29396591]

MeSH Term

Face
Humans
Platelet-Rich Fibrin
Platelet-Rich Plasma
Rejuvenation
Skin Aging
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0APCsfacialrejuvenationwellclinicalplatelet-richtrialsAutologousplateletconcentratestoleratedlowerskinPRPfavorablestudiesproductsfibrinevaluatecharacteristicsBACKGROUND:promisingtherapeuticagentssincegreatsourcecytokinesgrowthfactorsbiologicallyactivesubstancesObtainedpatient'sbloodadvantagesreducingimmunologicalreactionsmakingproceduresaferminimaladverseeffectscostCurrentlyusedcombinationmicroneedlingmesotherapytechniquestreatacnescarsmelasmawoundslaserablativetreatmentsreviewsummarizescurrentknowledgeuserangingbasicconceptsrelatedcompositionmechanismsactionup-to-dateinformationefficacyMETHODOLOGY:MEDLINEPubMedsearchedinception2021EnglishlanguagepublicationsRESULTS:total100filesfoundBasedavailableliteraturesafestudiedproductfirst-generationmaterialplasmaCONCLUSIONS:resultsgeneralqualitylowsecondthirdgenerationPRFinjectablei-PRFrespectivelyeasierobtainedleastvitroseeminducegreatercollagenproductionespeciallyrelativecentrifugationforcesdateevaluatingexisthigh-qualityappropriatefollow-upnecessaryprovideadequateevidencemayhelpimprovetreatmentregimensManyaspectsconsidereddesigningpatients'bestpredictresponseoptimalnumbersessionsintervaldevelopmentbetterinstrumentsaging

Similar Articles

Cited By